Process intensification

Process intensification

featured image of Sartorius and Sanofi Revolutionize Drug Manufacturing!

Sartorius and Sanofi Revolutionize Drug Manufacturing!

BIOT

🔬 Sartorius teams up with Sanofi to revolutionize drug manufacturing! 🌍💼 The collaboration aims to improve efficiency and sustainability. 🚀🏭

featured image of Master Your Biopharma Strategy: Avoid Over-Investing

Master Your Biopharma Strategy: Avoid Over-Investing

BIOT

📢 Process intensification in biopharma is complex and costly, but with data-driven strategies and step-by-step implementation, success is possible! 💪💰📈

featured image of AZ Accelerates Cell Therapy Production with FasTCAR: Faster Cheaper and Accessible

AZ Accelerates Cell Therapy Production with FasTCAR: Faster Cheaper and Accessible

BIOT

📢 AstraZeneca teams up with FasTCAR to fast-track cell therapy production, revolutionizing accessibility and affordability for patients. 🚀

featured image of Revolutionizing Biopharma: The Future of Model Predictive Control

Revolutionizing Biopharma: The Future of Model Predictive Control

BIOT

🌟 Model Predictive Control (MPC) uses mathematical models to anticipate future behavior, allowing for strategic adjustments in real-time. 💪 ⚙️ Technological advancements are improving the implementation of MPC, making it more accessible and feasible. ⏳ 💡 Integrating MPC with Process Analytical Technology (PAT) ensures precise and consistent product quality. 🚀

featured image of Biomanufacturing Goes Green: A Sustainable Revolution

Biomanufacturing Goes Green: A Sustainable Revolution

BIOT

🌿 Biomanufacturing aims for net-zero emissions by 2050, using renewable energy, reducing carbon footprint, and promoting recycling. 🌍🔬⚡🛢️💡

featured image of Revolutionary Kyverna Cuts CAR-T Production to 3 Days

Revolutionary Kyverna Cuts CAR-T Production to 3 Days

BIOT

📰 CAR-T, a gamechanger in cancer treatment, could revolutionize patient access and save lives with Kyverna's 3-day process. 💉🔬

featured image of Revolutionary System Boosts Lentiviral Vector Production

Revolutionary System Boosts Lentiviral Vector Production

BIOT

📝 Scaling-up production of lentiviral vectors (LV)-based therapies is a challenge for biomanufacturers. 😎🔬 McGill University researchers have developed a semi-continuous manufacturing system that enhances the quantity and recovery of LVs, reduces instability, and cuts processing time by four-fold. ⏱️💪 The system integrates upstream and downstream bioprocesses, resulting in significant time savings. 💡✨ It operates by rotating membranes between two systems, improving efficiency. 🔄🔝